Economic evaluation of sublingual immunotherapy vs symptomatic treatment in adults with pollen-induced respiratory allergy: The Sublingual Immunotherapy Pollen Allergy Italy (SPAI) study

Annals of Allergy, Asthma and Immunology

Volumn 97, Issue 5, 2006, Pages 615-621

  Berto, Patrizia ^a   Passalacqua, Giovanni ^b,h   Crimi, Nunzio ^c   Frati, Franco ^d,e   Ortolani, Claudio ^f   Senna, Gianenrico ^g   Canonica, Giorgio Walter ^b  

^a UNIVERSITY OF PADOVA   (Italy)

^b UNIVERSITY OF GENOA   (Italy)

^c UNIVERSITY OF CATANIA   (Italy)

^d UNIVERSITY OF PERUGIA   (Italy)

^e Rottapharm   (Italy)

^f Istituto Allergologico Lombardo   (Italy)

^g Verona General Hospital   (Italy)

^h Allergy and Respiratory Diseases   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHISTAMINIC AGENT; BECLOMETASONE; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; CORTICOSTEROID; DECONGESTIVE AGENT; IMMUNOMODULATING AGENT; STEROID;

ADOLESCENT; ADULT; ALLERGIC RHINITIS; ARTICLE; ASTHMA; COMPARATIVE STUDY; COST EFFECTIVENESS ANALYSIS; COST OF ILLNESS; DECISION THEORY; FEMALE; HEALTH CARE COST; HEALTH CARE SYSTEM; HEALTH CARE UTILIZATION; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; PALLIATIVE THERAPY; POLLEN ALLERGY; PRIORITY JOURNAL; RESPIRATORY TRACT ALLERGY; SENSITIVITY ANALYSIS; SYMPTOMATOLOGY; TREATMENT INDICATION; TREATMENT OUTCOME;

EID: 33845221962     PISSN: 10811206     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1081-1206(10)61090-3     Document Type: Article

References (33)

1. Bousquet J, Lockey R, Mailing HJ. Allergen immunotherapy: therapeutic vaccines for allergic diseases: a WHO position paper. J Allergy Clin Immunol. 1998;102:558-562.
2. Scadding K, Brostoff J. Low dose sublingual therapy in patients with allergic rhinitis due to dust mite. Clin Allergy. 1986;16:483-491.
3. Passalacqua G, Guerra L, Pasquali M, Lombardi C, Canonica GW. Efficacy and safety of sublingual immunotherapy. Ann Allergy Asthma Immunol. 2004;93:3-12.
4. Wilson DR, Torres LI, Durham SR. Sublingual immunotherapy for allergic rhinitis (Cochrane review). Cochrane Database Syst Rev. 2003;2:CD002893.
5. Penagos M, Compalati E, Baena Cagnani R, Passalacqua G, Canonica GW. Meta-analysis of sublingual immunotherapy in pediatric patients. Ann Allergy Asthma Immunol. In press.
6. Calamita Z, Saconato H, Bronhara Pelà A, Nagib Atallah A. Efficacy of sublingual immunotherapy in asthma: systematic review of randomized clinical trials. Allergy. In press.
7. Di Rienzo V, Musarra A, Sambugaro R, et al. Post marketing survey on the safety of sublingual immunotherapy in children below the age of 5 years. Clin Exp Allergy. 2005;35:560-564.
8. Lombardi C, Gargioni S, Melchiorre A, et al. Safety of sublingual immunotherapy in adults: a post marketing surveillance study. Allergy. 2001;56:889-892.
9. Fiocchi A, Pajno G, La Grutta S, et al. Safety of sublingual-swallow immunotherapy in children aged 3 to 7 years. Ann Allergy Asthma Immunol. 2005;95:254-258.
10. Pajno GB, Peroni DG, Vita D, Pietrobelli A, Parmiani S, Boner AL. Safety of sublingual immunotherapy in children with asthma. Paediatr Drugs. 2003;5:777-781.
11. Bousquet J, Van Cauwenberge P. Allergic Rhinitis and its Impact on Asthma. J Allergy Clin Immunol. 2001;108:S147-S334.
12. Novembre E, Galli E, Landi F, et al. Coseasonal sublingual immunotherapy reduces the development of asthma in children with allergic rhinoconjunctivitis. J Allergy Clin Immunol. 2004;114:851-857.
13. Marogna M, Spadolini I, Massolo A, Canonica GW, Passalacqua G. Randomized controlled open study of SLIT for respiratory allergy in real life: clinical efficacy and more. Allergy. 2004;59:1205-1210.
14. Di Rienzo V, Marcucci F, Puccinelli PF, et al. Long-lasting effect of sublingual immunotherapy in children with asthma due to house dust mite: a ten year prospective study. Clin Exp Allergy. 2003;33:206-210.
15. Canonica GW, Passalacqua G. Non injection routes for immunotherapy. J Allergy Clin Immunol. 2003;111:437-448.
16. Fadel R, Scheinmann P, Bousquet J, et al. Pharmaco-economic evaluation of specific immunotherapy versus symptomatic treatment of allergic rhinitis and asthma in France. Poster presented at: XXIII EAACI Congress; June 12-16, 2004; Amsterdam, the Netherlands.
17. Bousquet J, Scheinmann P, Neukirch F, et al. Pharmacoeconomic assessment of specific immunotherapy in the treatment of allergic rhinitis and asthma: relevance of a modeling approach. Poster presented at: XXIII EAACI Congress; June 12-16, 2004; Amsterdam, the Netherlands.
18. Global Initiative for Asthma (GINA). Workshop report: global strategy for asthma management and prevention. Update 2005. Available at 222.ginasthma.org. Accessed June 30, 2006.
19. Drummond M, O'Brien B, Stoddart G. Methods for the Economic Evaluation of Health Care Programmes. 2nd ed. Oxford, England: Oxford University Press; 1997:40-41.
20. Gold M, Siegel J Russell L. Cost-effectiveness in Health and Medicine. New York, NY: Oxford University Press; 1996:27-28.
21. Ministero della Sanità. Nomenclatore Tariffario delle prestazioni ambulatoriali DM 22.7.96. Gazzetta Ufficiale. 1996;216:14.9.96.
22. Ministero della Sanità. Aggiornamento delle tariffe delle prestazioni di assistenza ospedaliera di cui al DM 14.12.1994; DM 30.6.97. Supplemento Ordinario Gazzetta Ufficiale. 1997:2098.9.
23. Banca D'Italia. In: Proceedings of the Assemblea generale ordinaria dei partecipanti; Roma, Italy; May 31, 2003.
24. TESTO UNICO - Compensazione interregionale della mobilità sanitaria. Modifiche tecniche introdotte dai referenti regionali per l'anno di attività 2001 e successivi. Ed. Azygos srl. Milano, Italy: Giugno; 2003.
25. Wright AL, Holberg CJ, Martinez FD, Halonen M, Morgan W, Taussig LM. Epidemiology of physician-diagnosed allergic rhinitis in childhood. Pediatrics. 1994;94:895-901.
26. Settipane GA, Hagy GW, Settipane RJ. Long-term risk factors for developing asthma and allergic rhinitis: a 23-year follow-up study of college students. Allergy Proc. 1994;15:21-25.
27. Plaschke PP, Janson C, Norrman E, Bjornsson E, Ellbjar S, Jarvholm B. Onset and remission of allergic rhinitis and asthma and the relationship with atopic sensitization and smoking. Am J Respir Crit Care Med. 2000;162(3 pt 1):920-924.
28. Guerra S, Sherrill DL, Martinez FD, Barbee RA. Rhinitis as an independent risk factor for adult-onset asthma. J Allergy Clin Immunol. 2002;109:419-425.
29. Leynaert B, Bousquet J, Neukirch C, Liard R, Neukirch F. Perennial rhinitis: an independent risk factor for asthma in nonatopic subjects. J Allergy Clin Immunol. 1999;104:301-304.
30. Buxton MJ, Drummond MF. Modelling in economic evaluation: an unavoidable fact of life. Health Econ. 1997;6:217-227.
31. Berto P, Bassi M, Cadario G, Cantarutti L, Contiguglia R, Crivellaro MA. Immunotherapy and access to medical care in patients with rhinitis and asthma: the SIMAP database. Poster presented at: XXV EAACI Congress: Vienna, Austria; 2006.
32. Creticos PS, Reed CE, Norman PS, et al. Ragweed immunotherapy in adult asthma. N Engl J Med. 1996;334:501-506.
33. Schadlich PK, Brecht JG. Economic evaluation of specific immunotherapy versus symptomatic treatment of allergic rhinitis in Germany. Pharmacoeconomics. 200017:37-52.